Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06717919 · ClinicalTrials.gov registry record · Phase 4
HOPE Against Cancer Recurrence in HCC
A Phase 4 study of HCC and Liver Transplantation, sponsored by Philipp Dutkowski.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 220
- Enrollment target
- 20
- Study locations
NCT06717919 is a Phase 4 study of HCC and Liver Transplantation that is actively recruiting participants, run by Philipp Dutkowski. The registered enrollment target is 220 participants, above the 185-participant average among 13 other HCC trials with a reported enrollment target (19% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT06717919, a Phase 4 study of HCC and Liver Transplantation, is actively recruiting participants, sponsored by Philipp Dutkowski.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 220 participants
- Enrollment target
- 20
- Study locations
Study Summary
Liver transplantation is often performed to treat liver cancer, or hepatocellular carcinoma (HCC), in patients with impaired liver function due to cirrhosis. A shortcoming, however, is tumor recurrence after transplantation. Approximately 15 % of patients receiving livers develop recurrence and this depends on the quality of the liver received. Machine liver perfusion, for example, hypothermic oxygenated liver perfusion (HOPE), which means that the organ is perfused with an oxygen-rich fluid in a cold environment before transplantation, is a novel method to improve the quality of livers before implantation. The standard of care is cold storage without perfusion. The objective of this study is to compare the survival after tumor recurrence of patients after liver transplantation for HCC between perfused and not perfused livers. This study's hypothesis is that survival without tumor recurrence is improved when the liver is perfused before implantation. The study involves transplant centers worldwide, and adults with HCC waiting for liver transplantation are included. 220 Patients will be recruited within 12 months and then observed for at least 2 years after transplantation. To provide the most valid results, the patients will be randomly allocated to either the organ perfusion group or a control group with standard-of-care cold storage of the organ.
Conditions Studied
Interventions
- PROCEDURE Hypothermic oxygenated perfusion
- PROCEDURE Conventional cold storage
Study Locations (20)
Other
- Medical University of Innsbruck - Innsbruck
- Medical University of Vienna - Vienna
- University Hospitals Leuven - Leuven
- Institut de Recherche Expérimentale et Clinique (IREC) UCLouvain (Brussels) - Woluwe-Saint-Lambert
- Institute for Clinical and Experimental Medicine (IKEM) (Prague) - Prague
- Copenhagen University Hospital - Copenhagen
- Hôpital de la Croix-Rousse (Lyon) - Lyon
- Universitätsklinikum Essen - Essen
- University Medical Centre Hamburg-Eppendorf - Hamburg-Eppendorf
- Hannover Medical School - Hanover
- University of Heidelberg - Heidelberg
- University of Mainz - Mainz
- University of Munich Grosshadern - München
- Milano Institutio Nazionale dei Tumori (Milan) - Milan
- ASST Grande Ospedale Metropolitano Niguarda (Milan) - Milan
- Padova University Hospital - Padua
- Gemelli University Hospital - Rome
- University of Udine - Udine
New York
- Rutgers New Jersey Medical School (New York) - New York
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2025-08-01 |
| Est. Completion | 2028-01-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06717919
The ClinicalTrials.gov registry entry for NCT06717919 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 185-participant average among 13 other HCC trials with a reported enrollment target (19% higher). The listed sponsor is Philipp Dutkowski, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with HCC appearing as the primary indexed condition, and to 2 interventions - of which Hypothermic oxygenated perfusion is the first listed.
NCT06717919 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Other, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT06717919 about?
NCT06717919 is a clinical study titled "HOPE Against Cancer Recurrence in HCC". Liver transplantation is often performed to treat liver cancer, or hepatocellular carcinoma (HCC), in patients with impaired liver function due to cirrhosis. A shortcoming, however, is tumor recurrence after transplantation. Approximately 15 % of patients receiving livers develop recurrence and this...
What is the current status of trial NCT06717919?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 220 participants. The study started on 2025-08-01. Estimated completion is 2028-01-31.
What conditions does trial NCT06717919 study?
This clinical trial studies the following conditions: HCC, Liver Transplantation, Oncological Outcomes.
What interventions are being tested in trial NCT06717919?
The interventions under investigation include: Hypothermic oxygenated perfusion (PROCEDURE), Conventional cold storage (PROCEDURE).
Who is sponsoring clinical trial NCT06717919?
This trial is sponsored by Philipp Dutkowski, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06717919 being conducted?
This trial has 20 study locations across New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HCC
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Multi-analyte Blood Test Clinical Trial
RECRUITING
-
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
RECRUITING · Phase 2
-
Y-90 Treatment Response Using Transarterial Radioembolization
RECRUITING · Phase 2
-
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ Unresectable HCC
RECRUITING · Phase 1
-
Effect of the HCC Liver-Link Intervention
RECRUITING · NA
-
Optimizing Y90 Therapy for Radiation Lobectomy
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.